Zylox-Tonbridge Medical Technology Co., Ltd. (ZYLOXTB) disclosed a share buyback of 50,000 H shares on 29 April 2026 through on-market transactions on the Stock Exchange of Hong Kong.

The repurchase was executed within a price range of HKD 22.44–22.84, resulting in a volume-weighted average price of HKD 22.65 and a total consideration of HKD 1.13 million. All repurchased shares are being held as treasury shares.

Following the transaction, the number of issued shares (excluding treasury shares) fell from 327.65 million to 327.60 million, while treasury shares increased to 8.75 million. The company’s total issued share count remains unchanged at 336.35 million.

The buyback forms part of the share repurchase mandate approved on 30 May 2025, which authorises the repurchase of up to 31.96 million shares. Inclusive of the latest transaction, Zylox-Tonbridge has repurchased 5.93 million shares under this mandate, representing 1.81% of the issued share capital at the time the mandate was granted.

Under Hong Kong Listing Rule 10.06(3)(a), Zylox-Tonbridge is subject to a moratorium on issuing new shares or disposing of treasury shares until 29 May 2026.